Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 13 to 24 of 122 entries
Sorted by: Best Match Show Resources per page
Emerging therapeutic targets for cerebral edema.

Expert opinion on therapeutic targets

Jha RM, Raikwar SP, Mihaljevic S, Casabella AM, Catapano JS, Rani A, Desai S, Gerzanich V, Simard JM.
PMID: 34844502
Expert Opin Ther Targets. 2022 Jan 02;1-22. doi: 10.1080/14728222.2021.2010045. Epub 2022 Jan 02.

INTRODUCTION: Cerebral edema is a key contributor to death and disability in several forms of brain injury. Current treatment options are limited, reactive, and associated with significant morbidity. Targeted therapies are emerging based on a growing understanding of the...

Cite
Jha RM, Raikwar SP, Mihaljevic S, et al. Emerging therapeutic targets for cerebral edema. Expert Opin Ther Targets. 2022;1-22doi: 10.1080/14728222.2021.2010045.
Jha, R. M., Raikwar, S. P., Mihaljevic, S., Casabella, A. M., Catapano, J. S., Rani, A., Desai, S., Gerzanich, V., & Simard, J. M. (2022). Emerging therapeutic targets for cerebral edema. Expert opinion on therapeutic targets, 1-22. https://doi.org/10.1080/14728222.2021.2010045
Jha, Ruchira M, et al. "Emerging therapeutic targets for cerebral edema." Expert opinion on therapeutic targets vol. (2022): 1-22. doi: https://doi.org/10.1080/14728222.2021.2010045
Jha RM, Raikwar SP, Mihaljevic S, Casabella AM, Catapano JS, Rani A, Desai S, Gerzanich V, Simard JM. Emerging therapeutic targets for cerebral edema. Expert Opin Ther Targets. 2022 Jan 02;1-22. doi: 10.1080/14728222.2021.2010045. Epub 2022 Jan 02. PMID: 34844502.
Copy Download .nbib Format: NLM
The High Cost of Low Quality: Recurring Hypoglycemia in a 63-Year-Old Man.

Clinical chemistry

Provost RG, Downs JW, Wolf CE, Williams GR.
PMID: 34726697
Clin Chem. 2021 Nov 01;67(11):1450-1454. doi: 10.1093/clinchem/hvab174.

No abstract available.

Cite
Provost RG, Downs JW, Wolf CE, et al. The High Cost of Low Quality: Recurring Hypoglycemia in a 63-Year-Old Man. Clin Chem. 2021;67(11):1450-1454doi: 10.1093/clinchem/hvab174.
Provost, R. G., Downs, J. W., Wolf, C. E., & Williams, G. R. (2021). The High Cost of Low Quality: Recurring Hypoglycemia in a 63-Year-Old Man. Clinical chemistry, 67(11), 1450-1454. https://doi.org/10.1093/clinchem/hvab174
Provost, Rosellen G, et al. "The High Cost of Low Quality: Recurring Hypoglycemia in a 63-Year-Old Man." Clinical chemistry vol. 67,11 (2021): 1450-1454. doi: https://doi.org/10.1093/clinchem/hvab174
Provost RG, Downs JW, Wolf CE, Williams GR. The High Cost of Low Quality: Recurring Hypoglycemia in a 63-Year-Old Man. Clin Chem. 2021 Nov 01;67(11):1450-1454. doi: 10.1093/clinchem/hvab174. PMID: 34726697.
Copy Download .nbib Format: NLM
Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats.

Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society

Bin Jardan YA, Ahad A, Raish M, Ahmad A, Alam MA, Al-Mohizea AM, Al-Jenoobi FI.
PMID: 34400867
Saudi Pharm J. 2021 Jul;29(7):719-723. doi: 10.1016/j.jsps.2021.05.002. Epub 2021 May 20.

The aim of the present research was to describe the consequences of hyperlipidemia (HL) on the pharmacokinetics of glibenclamide (Gb) in poloxamer 407-induced hyperlipidemic rats. Rats were given intraperitoneal dose of poloxamer 407 to cause hyperlipidemia. A single oral...

Cite
Bin Jardan YA, Ahad A, Raish M, et al. Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats. Saudi Pharm J. 2021;29(7):719-723doi: 10.1016/j.jsps.2021.05.002.
Bin Jardan, Y. A., Ahad, A., Raish, M., Ahmad, A., Alam, M. A., Al-Mohizea, A. M., & Al-Jenoobi, F. I. (2021). Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats. Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society, 29(7), 719-723. https://doi.org/10.1016/j.jsps.2021.05.002
Bin Jardan, Yousef A, et al. "Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats." Saudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society vol. 29,7 (2021): 719-723. doi: https://doi.org/10.1016/j.jsps.2021.05.002
Bin Jardan YA, Ahad A, Raish M, Ahmad A, Alam MA, Al-Mohizea AM, Al-Jenoobi FI. Assessment of glibenclamide pharmacokinetics in poloxamer 407-induced hyperlipidemic rats. Saudi Pharm J. 2021 Jul;29(7):719-723. doi: 10.1016/j.jsps.2021.05.002. Epub 2021 May 20. PMID: 34400867; PMCID: PMC8347666.
Copy Download .nbib Format: NLM
Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease.

ACS pharmacology & translational science

Baruah P, Das A, Paul D, Chakrabarty S, Aguan K, Mitra S.
PMID: 33615172
ACS Pharmacol Transl Sci. 2021 Jan 06;4(1):193-205. doi: 10.1021/acsptsci.0c00168. eCollection 2021 Feb 12.

Contemporary literature documents extensive research on common causative mechanisms, pathogenic pathways and dual effective remedies for Alzheimer's disease (AD) and Type 2 diabetes mellitus (T2DM). Tolbutamide (TBM), chlorpropamide (CPM), and glyburide (GLY) are three sulfonylurea antidiabetic drugs of different...

Cite
Baruah P, Das A, Paul D, et al. Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease. ACS Pharmacol Transl Sci. 2021;4(1):193-205doi: 10.1021/acsptsci.0c00168.
Baruah, P., Das, A., Paul, D., Chakrabarty, S., Aguan, K., & Mitra, S. (2021). Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease. ACS pharmacology & translational science, 4(1), 193-205. https://doi.org/10.1021/acsptsci.0c00168
Baruah, Prayasee, et al. "Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease." ACS pharmacology & translational science vol. 4,1 (2021): 193-205. doi: https://doi.org/10.1021/acsptsci.0c00168
Baruah P, Das A, Paul D, Chakrabarty S, Aguan K, Mitra S. Sulfonylurea Class of Antidiabetic Drugs Inhibit Acetylcholinesterase Activity: Unexplored Auxiliary Pharmacological Benefit toward Alzheimer's Disease. ACS Pharmacol Transl Sci. 2021 Jan 06;4(1):193-205. doi: 10.1021/acsptsci.0c00168. eCollection 2021 Feb 12. PMID: 33615172; PMCID: PMC7887854.
Copy Download .nbib Format: NLM
Development of High-Risk Geriatric Polypharmacy Electronic Clinical Quality Measures and a Pilot Test of EHR Nudges Based on These Measures.

Journal of general internal medicine

Persell SD, Brown T, Doctor JN, Fox CR, Goldstein NJ, Handler SM, Hanlon JT, Lee JY, Linder JA, Meeker D, Rowe TA, Sullivan MD, Friedberg MW.
PMID: 34993860
J Gen Intern Med. 2022 Jan 06; doi: 10.1007/s11606-021-07296-1. Epub 2022 Jan 06.

BACKGROUND: Inappropriate polypharmacy, prevalent among older patients, is associated with substantial harms.OBJECTIVE: To develop measures of high-risk polypharmacy and pilot test novel electronic health record (EHR)-based nudges grounded in behavioral science to promote deprescribing.DESIGN: We developed and validated seven...

Cite
Persell SD, Brown T, Doctor JN, et al. Development of High-Risk Geriatric Polypharmacy Electronic Clinical Quality Measures and a Pilot Test of EHR Nudges Based on These Measures. J Gen Intern Med. 2022;doi: 10.1007/s11606-021-07296-1.
Persell, S. D., Brown, T., Doctor, J. N., Fox, C. R., Goldstein, N. J., Handler, S. M., Hanlon, J. T., Lee, J. Y., Linder, J. A., Meeker, D., Rowe, T. A., Sullivan, M. D., & Friedberg, M. W. (2022). Development of High-Risk Geriatric Polypharmacy Electronic Clinical Quality Measures and a Pilot Test of EHR Nudges Based on These Measures. Journal of general internal medicine, . https://doi.org/10.1007/s11606-021-07296-1
Persell, Stephen D, et al. "Development of High-Risk Geriatric Polypharmacy Electronic Clinical Quality Measures and a Pilot Test of EHR Nudges Based on These Measures." Journal of general internal medicine vol. (2022). doi: https://doi.org/10.1007/s11606-021-07296-1
Persell SD, Brown T, Doctor JN, Fox CR, Goldstein NJ, Handler SM, Hanlon JT, Lee JY, Linder JA, Meeker D, Rowe TA, Sullivan MD, Friedberg MW. Development of High-Risk Geriatric Polypharmacy Electronic Clinical Quality Measures and a Pilot Test of EHR Nudges Based on These Measures. J Gen Intern Med. 2022 Jan 06; doi: 10.1007/s11606-021-07296-1. Epub 2022 Jan 06. PMID: 34993860.
Copy Download .nbib Format: NLM
Traumatic Brain Injury Update.

AACN advanced critical care

Scarboro M, McQuillan KA.
PMID: 33725106
AACN Adv Crit Care. 2021 Mar 15;32(1):29-50. doi: 10.4037/aacnacc2021331.

Traumatic brain injury is a devastating, life-changing event in most cases. After the primary brain insult, it is helpful to use evidence-based monitoring techniques to guide implementation of essential interventions to minimize secondary injury and thereby improve patient outcomes....

Cite
Scarboro M, McQuillan KA. Traumatic Brain Injury Update. AACN Adv Crit Care. 2021;32(1):29-50doi: 10.4037/aacnacc2021331.
Scarboro, M., & McQuillan, K. A. (2021). Traumatic Brain Injury Update. AACN advanced critical care, 32(1), 29-50. https://doi.org/10.4037/aacnacc2021331
Scarboro, Maureen, and McQuillan, Karen A. "Traumatic Brain Injury Update." AACN advanced critical care vol. 32,1 (2021): 29-50. doi: https://doi.org/10.4037/aacnacc2021331
Scarboro M, McQuillan KA. Traumatic Brain Injury Update. AACN Adv Crit Care. 2021 Mar 15;32(1):29-50. doi: 10.4037/aacnacc2021331. PMID: 33725106.
Copy Download .nbib Format: NLM
Photosensitizing Medications and Skin Cancer: A Comprehensive Review.

Cancers

George EA, Baranwal N, Kang JH, Qureshi AA, Drucker AM, Cho E.
PMID: 34066301
Cancers (Basel). 2021 May 12;13(10). doi: 10.3390/cancers13102344.

(1) The incidence of skin cancer is increasing in the United States (US) despite scientific advances in our understanding of skin cancer risk factors and treatments. In vitro and in vivo studies have provided evidence that suggests that certain...

Cite
George EA, Baranwal N, Kang JH, et al. Photosensitizing Medications and Skin Cancer: A Comprehensive Review. Cancers (Basel). 2021;13(10)doi: 10.3390/cancers13102344.
George, E. A., Baranwal, N., Kang, J. H., Qureshi, A. A., Drucker, A. M., & Cho, E. (2021). Photosensitizing Medications and Skin Cancer: A Comprehensive Review. Cancers, 13(10), . https://doi.org/10.3390/cancers13102344
George, Elisabeth A, et al. "Photosensitizing Medications and Skin Cancer: A Comprehensive Review." Cancers vol. 13,10 (2021). doi: https://doi.org/10.3390/cancers13102344
George EA, Baranwal N, Kang JH, Qureshi AA, Drucker AM, Cho E. Photosensitizing Medications and Skin Cancer: A Comprehensive Review. Cancers (Basel). 2021 May 12;13(10). doi: 10.3390/cancers13102344. PMID: 34066301; PMCID: PMC8152064.
Copy Download .nbib Format: NLM
Effects of Different Glucose-Lowering Measures on Maternal and Infant Outcomes in Pregnant Women with Gestational Diabetes: A Network Meta-analysis.

Diabetes therapy : research, treatment and education of diabetes and related disorders

Ouyang H, Wu N.
PMID: 34482529
Diabetes Ther. 2021 Oct;12(10):2715-2753. doi: 10.1007/s13300-021-01142-7. Epub 2021 Sep 04.

INTRODUCTION: A network meta-analysis was conducted to compare and rank the effects of different glucose-lowering measures on maternal and infant outcomes in pregnant women with gestational diabetes mellitus (GDM).METHODS: We searched the PubMed, CNKI, Embase, Cochrane Library, Wanfang, and...

Cite
Ouyang H, Wu N. Effects of Different Glucose-Lowering Measures on Maternal and Infant Outcomes in Pregnant Women with Gestational Diabetes: A Network Meta-analysis. Diabetes Ther. 2021;12(10):2715-2753doi: 10.1007/s13300-021-01142-7.
Ouyang, H., & Wu, N. (2021). Effects of Different Glucose-Lowering Measures on Maternal and Infant Outcomes in Pregnant Women with Gestational Diabetes: A Network Meta-analysis. Diabetes therapy : research, treatment and education of diabetes and related disorders, 12(10), 2715-2753. https://doi.org/10.1007/s13300-021-01142-7
Ouyang, Hong, and Wu, Na. "Effects of Different Glucose-Lowering Measures on Maternal and Infant Outcomes in Pregnant Women with Gestational Diabetes: A Network Meta-analysis." Diabetes therapy : research, treatment and education of diabetes and related disorders vol. 12,10 (2021): 2715-2753. doi: https://doi.org/10.1007/s13300-021-01142-7
Ouyang H, Wu N. Effects of Different Glucose-Lowering Measures on Maternal and Infant Outcomes in Pregnant Women with Gestational Diabetes: A Network Meta-analysis. Diabetes Ther. 2021 Oct;12(10):2715-2753. doi: 10.1007/s13300-021-01142-7. Epub 2021 Sep 04. PMID: 34482529; PMCID: PMC8479018.
Copy Download .nbib Format: NLM
Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia.

Clinical pharmacology and therapeutics

Hee Nam Y, Brensinger CM, Bilker WB, Flory JH, Leonard CE, Hennessy S.
PMID: 34312836
Clin Pharmacol Ther. 2022 Jan;111(1):218-226. doi: 10.1002/cpt.2377. Epub 2021 Aug 23.

Serious hypoglycemia is a major adverse event associated with insulin secretagogues. Previous studies have suggested a potential relationship between angiotensin-converting enzyme inhibitors (ACEIs) used with sulfonylureas and serious hypoglycemia, and widely used drug compendia warn of this potential drug-drug...

Cite
Hee Nam Y, Brensinger CM, Bilker WB, et al. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clin Pharmacol Ther. 2021;111(1):218-226doi: 10.1002/cpt.2377.
Hee Nam, Y., Brensinger, C. M., Bilker, W. B., Flory, J. H., Leonard, C. E., & Hennessy, S. (2022). Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clinical pharmacology and therapeutics, 111(1), 218-226. https://doi.org/10.1002/cpt.2377
Hee Nam, Young, et al. "Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia." Clinical pharmacology and therapeutics vol. 111,1 (2022): 218-226. doi: https://doi.org/10.1002/cpt.2377
Hee Nam Y, Brensinger CM, Bilker WB, Flory JH, Leonard CE, Hennessy S. Angiotensin-Converting Enzyme Inhibitors Used Concomitantly with Insulin Secretagogues and the Risk of Serious Hypoglycemia. Clin Pharmacol Ther. 2022 Jan;111(1):218-226. doi: 10.1002/cpt.2377. Epub 2021 Aug 23. PMID: 34312836; PMCID: PMC8678147.
Copy Download .nbib Format: NLM
GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents.

Cardiology research and practice

Xiong QF, Fan SH, Li XW, Niu Y, Wang J, Zhang X, Chen YF, Shi YW, Zhang LH.
PMID: 31772770
Cardiol Res Pract. 2019 Oct 23;2019:1968785. doi: 10.1155/2019/1968785. eCollection 2019.

GLP-1 is a new type of antidiabetic agent that possesses many beneficial effects. Although its cardiovascular actions have been widely examined, little is known about GLP-1's effects on the rat coronary artery (RCA) or about the mechanisms underpinning these...

Cite
Xiong QF, Fan SH, Li XW, et al. GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents. Cardiol Res Pract. 2019;2019:1968785doi: 10.1155/2019/1968785.
Xiong, Q. F., Fan, S. H., Li, X. W., Niu, Y., Wang, J., Zhang, X., Chen, Y. F., Shi, Y. W., & Zhang, L. H. (2019). GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents. Cardiology research and practice, 20191968785. https://doi.org/10.1155/2019/1968785
Xiong, Qian-Feng, et al. "GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents." Cardiology research and practice vol. 2019 (2019): 1968785. doi: https://doi.org/10.1155/2019/1968785
Xiong QF, Fan SH, Li XW, Niu Y, Wang J, Zhang X, Chen YF, Shi YW, Zhang LH. GLP-1 Relaxes Rat Coronary Arteries by Enhancing ATP-Sensitive Potassium Channel Currents. Cardiol Res Pract. 2019 Oct 23;2019:1968785. doi: 10.1155/2019/1968785. eCollection 2019. PMID: 31772770; PMCID: PMC6854269.
Copy Download .nbib Format: NLM
Glyburide Regulates UCP1 Expression in Adipocytes Independent of K.

iScience

Qiu Y, Yang Y, Wei Y, Liu X, Feng Z, Zeng X, Chen Y, Liu Y, Zhao Y, Chen L, Luo L, Ding Q.
PMID: 32829287
iScience. 2020 Aug 10;23(9):101446. doi: 10.1016/j.isci.2020.101446. Epub 2020 Aug 10.

Identification of safe and effective compounds to increase or activate UCP1 expression in brown or white adipocytes remains a potent therapeutic strategy to combat obesity. Here we reported that, glyburide, one of the FDA-approved drugs currently used to treat...

Cite
Qiu Y, Yang Y, Wei Y, et al. Glyburide Regulates UCP1 Expression in Adipocytes Independent of K. iScience. 2020;23(9):101446doi: 10.1016/j.isci.2020.101446.
Qiu, Y., Yang, Y., Wei, Y., Liu, X., Feng, Z., Zeng, X., Chen, Y., Liu, Y., Zhao, Y., Chen, L., Luo, L., & Ding, Q. (2020). Glyburide Regulates UCP1 Expression in Adipocytes Independent of K. iScience, 23(9), 101446. https://doi.org/10.1016/j.isci.2020.101446
Qiu, Yan, et al. "Glyburide Regulates UCP1 Expression in Adipocytes Independent of K." iScience vol. 23,9 (2020): 101446. doi: https://doi.org/10.1016/j.isci.2020.101446
Qiu Y, Yang Y, Wei Y, Liu X, Feng Z, Zeng X, Chen Y, Liu Y, Zhao Y, Chen L, Luo L, Ding Q. Glyburide Regulates UCP1 Expression in Adipocytes Independent of K. iScience. 2020 Aug 10;23(9):101446. doi: 10.1016/j.isci.2020.101446. Epub 2020 Aug 10. PMID: 32829287; PMCID: PMC7452185.
Copy Download .nbib Format: NLM
Modulation of Placental Breast Cancer Resistance Protein by HDAC1 in Mice: Implications for Optimization of Pharmacotherapy During Pregnancy.

Reproductive sciences (Thousand Oaks, Calif.)

Wang C, Ma D, Hua Y, Duan H.
PMID: 34668144
Reprod Sci. 2021 Dec;28(12):3540-3546. doi: 10.1007/s43032-021-00773-2. Epub 2021 Oct 19.

Breast cancer resistance protein (BCRP/ABCG2) is a critical drug efflux transporters by limiting drugs' transplacental transfer rates. More investigations on the regulation of placental BCRP offer great promise for enabling pronounced progress in individualized and safe pharmacotherapy during pregnancy....

Cite
Wang C, Ma D, Hua Y, et al. Modulation of Placental Breast Cancer Resistance Protein by HDAC1 in Mice: Implications for Optimization of Pharmacotherapy During Pregnancy. Reprod Sci. 2021;28(12):3540-3546doi: 10.1007/s43032-021-00773-2.
Wang, C., Ma, D., Hua, Y., & Duan, H. (2021). Modulation of Placental Breast Cancer Resistance Protein by HDAC1 in Mice: Implications for Optimization of Pharmacotherapy During Pregnancy. Reproductive sciences (Thousand Oaks, Calif.), 28(12), 3540-3546. https://doi.org/10.1007/s43032-021-00773-2
Wang, Chuan, et al. "Modulation of Placental Breast Cancer Resistance Protein by HDAC1 in Mice: Implications for Optimization of Pharmacotherapy During Pregnancy." Reproductive sciences (Thousand Oaks, Calif.) vol. 28,12 (2021): 3540-3546. doi: https://doi.org/10.1007/s43032-021-00773-2
Wang C, Ma D, Hua Y, Duan H. Modulation of Placental Breast Cancer Resistance Protein by HDAC1 in Mice: Implications for Optimization of Pharmacotherapy During Pregnancy. Reprod Sci. 2021 Dec;28(12):3540-3546. doi: 10.1007/s43032-021-00773-2. Epub 2021 Oct 19. PMID: 34668144; PMCID: PMC8580892.
Copy Download .nbib Format: NLM
Showing 13 to 24 of 122 entries